Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company’s lead programs […]
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its target price decreased by SVB Leerink from $78.00 to $67.00 in a research report released on Tuesday, MarketBeat.com reports. SVB Leerink currently has an outperform rating on the stock. A number of other brokerages have also recently weighed in on ZNTL. Wells Fargo & Company initiated coverage […]
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its price target reduced by Stifel Nicolaus from $94.00 to $74.00 in a report issued on Monday, The Fly reports. Other analysts have also recently issued research reports about the company. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Wednesday, April 6th. They […]
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its target price decreased by analysts at Oppenheimer from $100.00 to $85.00 in a research note issued on Tuesday, The Fly reports. Oppenheimer’s price target points to a potential upside of 191.40% from the stock’s previous close. Several other analysts also recently issued reports on ZNTL. SVB Leerink […]
Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) in a research report report published on Wednesday, MarketBeat.com reports. The firm issued an overweight rating and a $67.00 price objective on the stock. ZNTL has been the topic of several other reports. SVB Leerink increased their price objective on […]